Aclaris Therapeutics (NASDAQ:ACRS) Releases Earnings Results, Misses Expectations By $0.03 EPS

Aclaris Therapeutics (NASDAQ:ACRS) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03), Zacks reports. The business had revenue of $4.35 million for the quarter, compared to analysts’ expectations of $8.31 million. Aclaris Therapeutics had a negative return on equity of 53.18% and a negative net margin of 183.28%.

Aclaris Therapeutics Price Performance

NASDAQ ACRS traded up $0.19 on Thursday, reaching $2.45. 1,005,888 shares of the company’s stock traded hands, compared to its average volume of 998,016. The stock has a market cap of $174.80 million, a PE ratio of -2.99 and a beta of 0.10. Aclaris Therapeutics has a 12 month low of $0.59 and a 12 month high of $5.61. The stock has a 50-day simple moving average of $1.32 and a 200 day simple moving average of $1.24.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. HC Wainwright reiterated a “neutral” rating on shares of Aclaris Therapeutics in a research report on Tuesday, September 17th. StockNews.com downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $9.00.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.